Business Description

Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Name Current Vs Industry Vs History
Cash-To-Debt 8077.63
Equity-to-Asset 0.95
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -18.1
3-Year EPS without NRI Growth Rate -19.2
3-Year FCF Growth Rate -10.1

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 39.58
9-Day RSI 41.1
14-Day RSI 42.37
6-1 Month Momentum % -0.33
12-1 Month Momentum % 40

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 21.89
Quick Ratio 21.89
Cash Ratio 21.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -22.3
Shareholder Yield % 0.58
Name Current Vs Industry Vs History
ROE % -24.13
ROA % -23.09
ROIC % -971.43
ROC (Joel Greenblatt) % -4542.03
ROCE % -27.65

Financials (Next Earnings Date:2024-04-24 Est.)

CYTT's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:CYTT

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Cyteir Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.94
Beta 0
Volatility % 21.1
14-Day RSI 42.37
14-Day ATR ($) 0.011961
20-Day SMA ($) 3.01
12-1 Month Momentum % 40
52-Week Range ($) 1.67 - 3.19
Shares Outstanding (Mil) 36

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cyteir Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Cyteir Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Cyteir Therapeutics Inc Frequently Asked Questions

What is Cyteir Therapeutics Inc(CYTT)'s stock price today?
The current price of CYTT is $3.01. The 52 week high of CYTT is $3.19 and 52 week low is $1.67.
When is next earnings date of Cyteir Therapeutics Inc(CYTT)?
The next earnings date of Cyteir Therapeutics Inc(CYTT) is 2024-04-24 Est..
Does Cyteir Therapeutics Inc(CYTT) pay dividends? If so, how much?
Cyteir Therapeutics Inc(CYTT) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1